BLS Pharmaceuticals Limited · ASX:BLS
BLS Pharmaceuticals — VRI Biomedical — Investor Presentation (March 2005)
17 slides from BLS Pharmaceuticals's investor presentation, March 2005
Slide 1: VRI Biomedical Limited Briefing
VRI Biomedical Limited –Second level Briefing Kim Slatyer – CEO Sydney – March 2005 bringing science to wellnessTM VRI Biomedical 1
Slide 2: Board
Board –Second level • Sir Victor Garland (Ch) • Mr Geoff Wild AM • Prof Ron Penny AO • Mr Bryan Gardiner bringing science to wellnessTM VRI Biomedical 2
Slide 3: Management
Management –Second level Management (14) • Administration (3) • Marketing & Development (7) • Research & Development (4) Sydney office at the ATP UNSW laboratories Multi-site clinical trials bringing science to wellnessTM VRI Biomedical 3
Slide 4: Turnaround
Turnaround –Second level • Poor corporate history • New management and board • Eight months of restructuring: – Technology focus from 3 to 1 – Spend from $5.5 to $3.4m – Revenue up 247% – Market Cap up 70% • Three licensing deals with major companies in past month = 3rd party validation • Promotiona
Slide 5: Business Model
Business Model –Second level • Technology = Probiotics • 3 channels to market: • Demonstrate brand potential through marketing therapeutic products in Australia (2% of global market) • License brands for overseas marketing and distribution • Maintain pipeline of products from clinical trial activity
Slide 6: Probiotics
Probiotics –Second level • Genetically typed and patented (pending): Lactobacillus fermentum VRI003 = PCC® • Unique polysaccharide coating • Mechanism of action described • Proven anti-inflammatory action VRI aims to provide highest level of scientific validation to Probiotics bringing science to we
Slide 7: L.fermentum VRI003
L.fermentum VRIOO3® –Second level bringing science to wellnessTM VRI Biomedical 7
Slide 8: Channels to Market
Channels to Market –Second level 1. Therapeutics 2. Functional Food 3. Biopharmaceuticals bringing science to wellnessTM VRI Biomedical 8
Slide 9: 1. Therapeutics
1. Therapeutics –Second level • VRI markets proTract® in Australian pharmacies • 58% margin • License to Zuellig for marketing in SE Asia • AD launch in April • AAD launch – end 2005 bringing science to wellnessTM VRI Biomedical 9
Slide 10: 2. Functional Foods
2. Functional Foods –Second level • Food’s with “wellness” or health claims. $US21Bn by 2007 • PCC® licensed to Sanitarium and Aust major • Exclusive deals by product and region • Typical deal = 5% royalty on sales • Product examples • Current objective to find global partners bringing science to we
Slide 11: 3. Biopharmaceuticals - Probiomics
3. Biopharmaceuticals –Second level “Probiomics” “The study and characterisation of the molecules that mediate the interaction between probiotic bacteria and the human body” • R&D with the Rowett Institute Stage 1 - Mechanism of action. Complete. Stage 2 - Identification novel molecules. bringing sc
Slide 12: Financials
Financials –Second level • Spend = $3.4m • Cash = $0.88m(12/04) + placement • Current revenue = $2.75m gross $850k net • New revenue streams – proTract® Atopic Dermatitis in April – proTract® in Malaysia in May – proTract® Antibiotic Associated Diarrhoea in Q4 – Food products in Australia in Q4 • 16
Slide 13: Value drivers in 2005: Therapeutics
Value drivers in 2005 –Second level • Therapeutics – Growth of proTract sales in Australian pharmacies. Production and Distribution issues resolved. – AD launch in April – Product launch in Malaysia in May – AAD launch end of 2005 – Possible licensing of brand in Australia bringing science to wellne
Slide 14: Value drivers in 2005: Functional Food
Value drivers in 2005 –Second level • Functional Food – Product launch in Q4 from existing deals – Discussions underway with global food companies – Infant formula bringing science to wellnessTM VRI Biomedical 14
Slide 15: Value drivers in 2005: Biopharmaceuticals
Value drivers in 2005 –Second level • Biopharmaceuticals – Commencement of program in May – Initial molecular discovery – Possible “big-Pharma” partnering bringing science to wellnessTM VRI Biomedical 15
Slide 16: Value drivers in 2005: Corporate activity
Value drivers in 2005 –Second level • Corporate activity – Spinout/licensing of diagnostics and vaccines – Dual AIM listing – Possible M&A activity – Corporate promotion bringing science to wellnessTM VRI Biomedical 16
Slide 17: Capital Structure
Capital Structure –Second level Ordinary fully paid shares 105m $0.18 Market Capitalisation $20m Cash as at 31/12/04 $0.88 52 wk high $0.26 52 wk low $0.10 Av. mthly volume 9.4m bringing science to wellnessTM VRI Biomedical 17